Yichang HEC Changjiang Pharmaceutical's Merger Offeror Agreed to License-out Product for $938 Million

MT Newswires Live

Nov 13, 2024

Yichang HEC Changjiang Pharmaceutical (HKG:1558) and Sunshine Lake Pharma said in a joint announcement that Sunshine has agreed to provide an exclusive license for APL-18881 (HEC88473) to Apollo Therapeutics Group for $938 million, a Tuesday Hong Kong bourse filing said.

Sunshine, the offeror to the merger by absorption of the company, will retain the development, manufacturing, and commercialization rights of APL-18881 (HEC88473) while Apollo will have the same rights in the rest of the world for at least 10 years.

Under the agreement, Sunshine can receive up to $938 million in payments including an upfront amount of $12 million. The development, regulatory, and commercial milestone payments can go up to $926 million. Sunshine may also receive royalties ranging from high single to low double-digit percentages of the net sales outside China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2483100891"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2483100891\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2483100891?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-13 19:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483100891","market":"nz","top_or_hot":-1,"title":"Yichang HEC Changjiang Pharmaceutical's Merger Offeror Agreed to License-out Product for $938 Million","media":"MT Newswires Live","content":"<html><body><p> Yichang HEC Changjiang Pharmaceutical (HKG:1558) and Sunshine Lake Pharma said in a joint announcement that Sunshine has agreed to provide an exclusive license for APL-18881 (HEC88473) to Apollo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Group for $938 million, a Tuesday Hong Kong bourse filing said.</p><p>Sunshine, the offeror to the merger by absorption of the company, will retain the development, manufacturing, and commercialization rights of APL-18881 (HEC88473) while Apollo will have the same rights in the rest of the world for at least 10 years.</p><p>Under the agreement, Sunshine can receive up to $938 million in payments including an upfront amount of $12 million. The development, regulatory, and commercial milestone payments can go up to $926 million. Sunshine may also receive royalties ranging from high single to low double-digit percentages of the net sales outside China.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Yichang HEC Changjiang Pharmaceutical's Merger Offeror Agreed to License-out Product for $938 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYichang HEC Changjiang Pharmaceutical's Merger Offeror Agreed to License-out Product for $938 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-13 19:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Yichang HEC Changjiang Pharmaceutical (HKG:1558) and Sunshine Lake Pharma said in a joint announcement that Sunshine has agreed to provide an exclusive license for APL-18881 (HEC88473) to Apollo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Group for $938 million, a Tuesday Hong Kong bourse filing said.</p><p>Sunshine, the offeror to the merger by absorption of the company, will retain the development, manufacturing, and commercialization rights of APL-18881 (HEC88473) while Apollo will have the same rights in the rest of the world for at least 10 years.</p><p>Under the agreement, Sunshine can receive up to $938 million in payments including an upfront amount of $12 million. The development, regulatory, and commercial milestone payments can go up to $926 million. Sunshine may also receive royalties ranging from high single to low double-digit percentages of the net sales outside China.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2483100891","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483100891","pubTimestamp":1731497293,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Yichang HEC Changjiang Pharmaceutical  and Sunshine Lake Pharma said in a joint announcement that Sunshine has agreed to provide an exclusive license for APL-18881  to Apollo Therapeutics Group for $938 million, a Tuesday Hong Kong bourse filing said.Sunshine, the offeror to the merger by absorption of the company, will retain the development, manufacturing, and commercialization rights of APL-18881  while Apollo will have the same rights in the rest of the world for at least 10 years.Under the agreement, Sunshine can receive up to $938 million in payments including an upfront amount of $12 million. The development, regulatory, and commercial milestone payments can go up to $926 million. Sunshine may also receive royalties ranging from high single to low double-digit percentages of the net sales outside China.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","01558":"东阳光长江药业","BK1191":"制药"},"translate_title":"宜昌东阳光长江药业的合并要约人同意以9.38亿美元授权产品","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01558":0.9},"content_text":"Yichang HEC Changjiang Pharmaceutical (HKG:1558) and Sunshine Lake Pharma said in a joint announcement that Sunshine has agreed to provide an exclusive license for APL-18881 (HEC88473) to Apollo Therapeutics Group for $938 million, a Tuesday Hong Kong bourse filing said.Sunshine, the offeror to the merger by absorption of the company, will retain the development, manufacturing, and commercialization rights of APL-18881 (HEC88473) while Apollo will have the same rights in the rest of the world for at least 10 years.Under the agreement, Sunshine can receive up to $938 million in payments including an upfront amount of $12 million. The development, regulatory, and commercial milestone payments can go up to $926 million. Sunshine may also receive royalties ranging from high single to low double-digit percentages of the net sales outside China.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}